Oxaliplatin, a Potent Inhibitor of Survivin, Enhances Paclitaxel-induced Apoptosis and Mitotic Catastrophe in Colon Cancer Cells
Authors:
- Hirofumi YamamotoHYHirofumi Yamamoto
- Chew Yee NganCNChew Yee Ngan
- Akimitsu TakagiATAkimitsu Takagi
- Taro HayashiTHTaro Hayashi
- Rei SuzukiRSRei Suzuki
- Koji EzumiKEKoji Ezumi
- Ichiro TakemasaITIchiro Takemasa
- Masataka IkedaMIMasataka Ikeda
- Mitsugu SekimotoMSMitsugu Sekimoto
- Nariaki MatsuuraNMNariaki Matsuura
- Morito MondenMMMorito Monden
Open Access
- 15 July 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 35 (8) , 453-463
Abstract
Background: Clinical studies have demonstrated that oxaliplatin, a novel platinum derivative, is a potent chemotherapeutic agent, especially when combined with other reagents. The aim of the present study was to explore the mechanism of such action. Methods: Using colon cancer cell lines, we examined changes in cell cycle, apoptosis and mitotic catastrophe induced by oxaliplatin and/or paclitaxel. Results: Oxaliplatin at its IC50 induced apoptosis and cell cycle arrest at G2–M phase. Western blot analyses indicated that oxaliplatin decreased mitosis-commencing protein cdc2 and anti-apoptotic proteins, phospho-Bcl2 and Bcl-xl in the three colon cancer cells tested. Since cdc2 stabilizes survivin, a putative IAP (inhibitor of apoptosis) family member, through phosphorylation of Thr34, we examined the level of survivin and found a marked decrease due to oxaliplatin. This finding is of particular interest because survivin is a promising molecular target against various human cancers and a key molecule involved in both apoptosis and mitotic catastrophe. When used in combination with paclitaxel (taxol), a putative apoptosis-inducing reagent, the isobologram indicated that the taxol–oxaliplatin sequence or taxol plus oxaliplatin had synergic or additive effects, while the oxaliplatin–taxol sequence resulted in a prominent antagonism. The taxol–oxaliplatin sequence caused marked growth inhibition of DLD1 and SW480 cells, possibly due to upregulation of apoptotic and non-apoptotic pathways, respectively. Morphological surveys indicated that the non-apoptotic process could be mitotic catastrophe. Conclusion: Our results suggest that oxaliplatin that potently inhibited survivin may exert outstanding cytotoxic effects when combined with certain chemoreagents through enhancement of apoptosis and mitotic catastrophe.Keywords
This publication has 43 references indexed in Scilit:
- Guidelines 2000 for Colon and Rectal Cancer SurgeryJNCI: Journal of the National Cancer Institute, 2001
- Molecular Modeling of the Intrastrand Guanine-Guanine DNA Adducts Produced by Cisplatin and OxaliplatinMolecular Pharmacology, 1999
- Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panelBiochemical Pharmacology, 1996
- Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancerBritish Journal of Cancer, 1996
- A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinomaCancer, 1993
- Biophysical analysis of DNA modified by 1,2-diaminocyclohexane platinum(II) complexesNucleic Acids Research, 1992
- Effect of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethalityBiochemistry, 1990
- Characterization of adducts produced in DNA by isomeric 1,2-diaminocyclohexaneplatinum(II) complexesChemico-Biological Interactions, 1989
- Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental dataBiomedicine & Pharmacotherapy, 1989
- Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinumBiomedicine & Pharmacotherapy, 1989